Ruggiero Salvatore L
New York Center for Orthognathic and Maxillary Surgery, Lake Success, New York, USA.
Compend Contin Educ Dent. 2008 Mar;29(2):96-8, 100-2, 104-5.
Bisphosphonates are a class of agents whose efficacy in treating and preventing the skeletal complications associated with osteoporosis and malignant bone metastases has been well established. Despite this benefit, osteonecrosis of the jaws is a significant complication in a subset of patients receiving these drugs. Based on a growing number of case reports and institutional reviews, bisphosphonate therapy may cause bone to become exposed and necrotic. Currently, this phenomenon is isolated to the jaw. This complication usually presents following simple dentoalveolar surgery. The pathogenesis for this complication appears to be related to the profound inhibition of osteoclast function and bone remodeling. This article serves to alert ists and dental specialists about the potential complication of jaw necrosis in patients receiving bisphosphonate therapy, and proposes a guideline for diagnosis, staging and management.
双膦酸盐是一类药物,其在治疗和预防与骨质疏松症及恶性骨转移相关的骨骼并发症方面的疗效已得到充分证实。尽管有此益处,但颌骨坏死是接受这些药物治疗的一部分患者的严重并发症。基于越来越多的病例报告和机构综述,双膦酸盐治疗可能导致骨暴露和坏死。目前,这种现象仅限于颌骨。这种并发症通常在简单的牙槽外科手术后出现。这种并发症的发病机制似乎与破骨细胞功能和骨重塑的深度抑制有关。本文旨在提醒医生和牙科专家注意接受双膦酸盐治疗的患者发生颌骨坏死的潜在并发症,并提出诊断、分期和管理指南。